Evidence map›Paper›PMID 22706959›Full record

ArticleParasitology research2012

Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine susceptibility 8 years after cessation of chloroquine use in Pikine, Senegal.

Omar Ly, Papa ElHadji Omar Gueye, Awa Bineta Deme, Therese Dieng, Aida Sadikh Badiane, Ambroise D Ahouidi, Mouhamadou Diallo, Amy K Bei, Dyann F Wirth, Souleymane Mboup and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Omar LyLaboratoire de Bacterio-Virologie, Hopital Aristide Le Dantec, 30 Avenue Pasteur, Dakar, Senegal.
Papa ElHadji Omar Gueye
Awa Bineta Deme
Therese Dieng
Aida Sadikh Badiane
Ambroise D Ahouidi
Mouhamadou Diallo
Amy K Bei
Dyann F Wirth
Souleymane Mboup
Ousmane Sarr
Hôpital Aristide Le Dantec · SNHarvard University · USCheikh Anta Diop University · SN

Funding

TRAINING IN MALARIA PATHOGENESIS AND DIVERSITY IN AFRICAD43TW001503 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WIRTH, DYANN F · 2000 to 2009
$1.6M
FIC NIH HHS 1.2D43TW01503
6 · The paper itself

Abstract

The goal of the present study was to assess the evolution of the in vitro chloroquine resistance and also the prevalence of pfcrt T76 and pfmdr1 Y86 mutations in Pikine from 2000 while chloroquine (CQ) was the first-line treatment of malaria to 2009 when artemisinin-based combination therapies (ACTs) are in use. We genotyped pfcrt K76T and pfmdr1 N86Y polymorphisms by PCR-RFLP and assessed in vitro CQ susceptibility by double-site enzyme-linked pLDH immunodetection (DELI) assay in Plasmodium falciparum isolates collected in Pikine, Senegal. The proportions of the pfcrt T76 allele in the light of the three different treatment policies were 72.4 % before CQ withdrawal (2000 to 2003), 47.2% while amodiaquine plus Fansidar was the first-line treatment (2004 to 2005), and 59.5 % since the ACT use was implemented (2006 to 2009). The prevalence of pfcrt T76 decreased significantly after CQ was stopped [X (2) = 6.54, P = 0.01 (2000-2003 versus 2004-2005)] and then slightly since ACTs have been implemented [X(2) = 1.12, P = 0.28 (2000-2003 versus 2006-2009)]. There were no significant differences on the prevalence of pfmdr1 Y86 throughout the three treatment policies. The DELI assay was carried out episodically in 2000 (n = 36), 2001 (n = 47), and 2009 (n = 37). The mean IC(50)s of the isolates to CQ in 2000 versus 2009 and 2001 versus 2009 are significantly different (P < 0.05). The Fisher exact test found a significant association between the presence of the pfcrt T76 mutant allele and in vitro resistance in 2000/2001 (P = 0.023), while in 2009 there were no association between both variables (P = 0.274). Mutant pfcrt T76 and pfmdr1 Y86 alleles and in vitro CQ-resistant strains are still circulating in Pikine. The official discontinuation of CQ use is not completely followed by its total withdrawal from private drug sellers, and the molecule still exerts pressure on local P. falciparum populations.

Indexed as

Drug ResistanceMutation, MissenseAntimalarialsATP-Binding Cassette, Sub-Family C ProteinsChloroquineDNA, ProtozoanDrug UtilizationGene FrequencyHumansMalaria, FalciparumMembrane Transport ProteinsParasitic Sensitivity TestsPlasmodium falciparumPoint MutationPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthAntimalarialsATP-Binding Cassette, Sub-Family C ProteinsChloroquineDNA, ProtozoanMdr1 protein, Plasmodium falciparumMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan Proteins

Identifiers

PMID22706959
OpenAlexW2066163022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.